Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Fecal Immunochemical Test Screens for Colon Cancer

By LabMedica International staff writers
Posted on 14 Dec 2010
A test that detects blood in the stool is the most cost effective method for screening for colon cancer. More...
An economic evaluation of screening methods for colorectal cancer found that annual testing by the fecal immunochemical methods was more effective than other methods.

The fecal immunochemical test has high sensitivity and specificity, and might improve participation rates through increased patient acceptability. This would reduce the risk of colorectal cancer and colorectal cancer related deaths, and reduce healthcare costs in comparison to all other screening strategies and to no screening. In a model devised by scientists at University of Calgary, (Alberta, Canada), the authors used an incremental cost utility analysis, a sophisticated modeling technique, and two hypothetical patient cohorts (individuals with an "average risk,” i.e., no family history of colorectal cancer, aged 50-64 and 65-75) to compare different colorectal cancer screening methods.

The authors found that annual fecal immunochemical testing was more effective and less costly compared to all strategies (including no screening). Using this screening modality, among the lifetimes of 100,000 average-risk patients, the number of deaths from colorectal cancer was reduced from 1,393 to 457. Even after the authors accounted for many different scenarios, screening for colorectal cancer with fecal immunochemical testing remained the most cost effective screening option.

Clinical guidelines recommends screening for colorectal cancer in average risk individuals from 50 years old, yet some countries, such as the UK, do not currently have population-based colorectal cancer screening. In addition, many countries with colorectal cancer screening programs do not offer a choice of screening method. The authors concluded: "Health policy decision makers should consider prioritizing funding for colorectal cancer screening using fecal immunochemical testing." The study was published online on November 23, 2010, in the open access journal Public Library of Science (PLoS) Medicine.

Related Links:
University of Calgary




Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.